US20020034275A1 - Method of strontium-89 radioisotope production - Google Patents
Method of strontium-89 radioisotope production Download PDFInfo
- Publication number
- US20020034275A1 US20020034275A1 US09/538,333 US53833300A US2002034275A1 US 20020034275 A1 US20020034275 A1 US 20020034275A1 US 53833300 A US53833300 A US 53833300A US 2002034275 A1 US2002034275 A1 US 2002034275A1
- Authority
- US
- United States
- Prior art keywords
- strontium
- gas
- krypton
- decay
- filter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CIOAGBVUUVVLOB-OUBTZVSYSA-N strontium-89 Chemical compound [89Sr] CIOAGBVUUVVLOB-OUBTZVSYSA-N 0.000 title claims abstract description 38
- 229940006509 strontium-89 Drugs 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims description 20
- 238000004519 manufacturing process Methods 0.000 title description 12
- 230000004992 fission Effects 0.000 claims abstract description 16
- CIOAGBVUUVVLOB-NJFSPNSNSA-N Strontium-90 Chemical compound [90Sr] CIOAGBVUUVVLOB-NJFSPNSNSA-N 0.000 claims abstract description 11
- 229910000384 uranyl sulfate Inorganic materials 0.000 claims abstract description 8
- 229910052701 rubidium Inorganic materials 0.000 claims abstract description 6
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910052743 krypton Inorganic materials 0.000 claims abstract description 4
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 claims abstract description 4
- FWFGVMYFCODZRD-UHFFFAOYSA-N oxidanium;hydrogen sulfate Chemical compound O.OS(O)(=O)=O FWFGVMYFCODZRD-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229910052790 beryllium Inorganic materials 0.000 claims abstract 2
- ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 claims abstract 2
- DNNSSWSSYDEUBZ-BKFZFHPZSA-N krypton-89 Chemical compound [89Kr] DNNSSWSSYDEUBZ-BKFZFHPZSA-N 0.000 claims description 15
- 229910052712 strontium Inorganic materials 0.000 claims description 13
- 238000001556 precipitation Methods 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 10
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 238000005086 pumping Methods 0.000 claims description 4
- 230000002285 radioactive effect Effects 0.000 claims description 4
- 239000007789 gas Substances 0.000 description 25
- 239000000243 solution Substances 0.000 description 23
- 239000000446 fuel Substances 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000011261 inert gas Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000003444 anaesthetic effect Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 229910001631 strontium chloride Inorganic materials 0.000 description 3
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 2
- 206010027452 Metastases to bone Diseases 0.000 description 2
- 229910052770 Uranium Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000005253 cladding Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- IGLNJRXAVVLDKE-RNFDNDRNSA-N rubidium-89 Chemical compound [89Rb] IGLNJRXAVVLDKE-RNFDNDRNSA-N 0.000 description 2
- 229910000018 strontium carbonate Inorganic materials 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000156978 Erebia Species 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005255 beta decay Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- BDAGIHXWWSANSR-NJFSPNSNSA-N hydroxyformaldehyde Chemical compound O[14CH]=O BDAGIHXWWSANSR-NJFSPNSNSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 201000011061 large intestine cancer Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- SIWVEOZUMHYXCS-UHFFFAOYSA-N oxo(oxoyttriooxy)yttrium Chemical compound O=[Y]O[Y]=O SIWVEOZUMHYXCS-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000191 radiation effect Effects 0.000 description 1
- 239000002901 radioactive waste Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000012958 reprocessing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- LEDMRZGFZIAGGB-UHFFFAOYSA-L strontium carbonate Chemical compound [Sr+2].[O-]C([O-])=O LEDMRZGFZIAGGB-UHFFFAOYSA-L 0.000 description 1
- CIOAGBVUUVVLOB-OIOBTWANSA-N strontium-85 Chemical compound [85Sr] CIOAGBVUUVVLOB-OIOBTWANSA-N 0.000 description 1
- 229940084642 strontium-89 chloride Drugs 0.000 description 1
- AHBGXTDRMVNFER-FCHARDOESA-L strontium-89(2+);dichloride Chemical compound [Cl-].[Cl-].[89Sr+2] AHBGXTDRMVNFER-FCHARDOESA-L 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000013066 thyroid gland cancer Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- JFALSRSLKYAFGM-FTXFMUIASA-N uranium-233 Chemical compound [233U] JFALSRSLKYAFGM-FTXFMUIASA-N 0.000 description 1
- JFALSRSLKYAFGM-OIOBTWANSA-N uranium-235 Chemical compound [235U] JFALSRSLKYAFGM-OIOBTWANSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- VWQVUPCCIRVNHF-IGMARMGPSA-N yttrium-89 atom Chemical compound [89Y] VWQVUPCCIRVNHF-IGMARMGPSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21C—NUCLEAR REACTORS
- G21C19/00—Arrangements for treating, for handling, or for facilitating the handling of, fuel or other materials which are used within the reactor, e.g. within its pressure vessel
- G21C19/28—Arrangements for introducing fluent material into the reactor core; Arrangements for removing fluent material from the reactor core
- G21C19/30—Arrangements for introducing fluent material into the reactor core; Arrangements for removing fluent material from the reactor core with continuous purification of circulating fluent material, e.g. by extraction of fission products deterioration or corrosion products, impurities, e.g. by cold traps
- G21C19/307—Arrangements for introducing fluent material into the reactor core; Arrangements for removing fluent material from the reactor core with continuous purification of circulating fluent material, e.g. by extraction of fission products deterioration or corrosion products, impurities, e.g. by cold traps specially adapted for liquids
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
- G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
- G21G1/02—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes in nuclear reactors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E30/00—Energy generation of nuclear origin
- Y02E30/30—Nuclear fission reactors
Definitions
- the present invention is in the field of radioisotope production and in particular relates to a method of producing strontium-89.
- Radioisotopes have been used in nuclear medicine for diagnostics and therapeutics for more than fifty years. Medical radioisotope production is an important industry using more than 50% of the radioisotopes produced in the world. More than 160 radioisotopes of 80 chemical elements are produced with the help of nuclear reactors and charged particle accelerators today.
- strontium-89 One of the most effective modern therapeutic radioisotopes is strontium-89. It is used for pain palliation instead of drugs when treating cancer. When medicine containing strontium-89 is introduced into an organism, it is absorbed and distributed in the bone metastases providing for a long anesthetic effect.
- Strontium-89 radioisotope has a half-life of 52.7 days with ⁇ decay (decays to Y 89 , a stable isotope).
- the maximum energy of the ⁇ -particles is 1463 keV.
- the attendant y-radiation energy is 909.1 keV.
- Strontium is a biochemical analog of calcium that has the same transport mechanism in the human body.
- Strontium chloride SrCl 2 introduced to the vein is mainly accumulated in bone metastases providing for a long anesthetic effect so it is not necessary to take drugs frequently and the patient does not become tolerant of them.
- Malignant tumors tending to metastases in the skeleton are: mammary gland, large intestine, thyroid gland, prostate, kidney, and skin cancer.
- the maximum range of ⁇ -particles of strontium-89 in the bone does not exceed 7 mm, so its radiation effects are isolated to the small area of the skeleton and its radiation burden on the marrow and nearby soft tissue is not significant.
- strontium-89 As strontium-89 is incorporated in the mineral structure of the bone, diseased metabolism does not take place, and it remains there for more than 100 days. Healthy bone contains a small component of the injected dose and loses it quickly during the first fortnight.
- One injection of strontium chloride is about 4 mCi and is effective for 3 to 6 months.
- Clinical tests of the preparation based on 89 SrCl 3 showed that 65-76% of the patients said that pain had been reduced significantly, and there was full anaesthetic effect in 20% of the cases.
- One reactor method of strontium-89 production consists of irradiating a target of strontium carbonate SrCO 3 with neutrons having a thermal neutron spectrum.
- a target made from metallic strontium is irradiated by the neutron flux of a nuclear reactor.
- Natural strontium consists of the following isotopes: Sr 84 at 0.56%, Sr 86 at 9.9%, Sr 87 at 7.0% and Sr 88 at 82.6%.
- the strontium-89 radioisotope is formed in the target as a result of the neutron capture reaction of one of the strontium isotopes Sr 88 (n,y) Sr 89 .
- a highly enriched target containing Sr 88 >99.9% is used because it is necessary to eliminate strontium-85 from the reaction Sr 84 (n,y) Sr 85 , an undesirable admixture. This is a convenient production method and takes place in a normal research reactor. The cross-section of the (n,y)-reaction is only 6 ⁇ 10 ⁇ 27 cm 2 , however, which restricts the productivity of this method.
- Another strontium-89 production method is based the threshold reaction of neutron capture with the emission of a charged particle Y 89 (n,p) Sr 89 .
- a target containing natural monoisotope Yttrium-89 is irradiated in the neutron flux of a nuclear reactor with a fast neutron spectrum and is subsequently subjected to radiochemical reprocessing for extraction.
- Strontium-89 production can achieve about 10-15 mCi per gram of yttrium in optimum conditions.
- the target is a pellet of yttrium oxide Y 2 O 3 of high purity that is pressed and annealed at 1600° C. This method produces almost no radioactive wastes and the end-product does not contain harmful admixtures, e.g., the quantity of attendant strontium-90 is less than 2 ⁇ 10 ⁇ 4 atomic percent.
- This method has an extremely low productivity due to the small cross-section of the (n,p)-reaction on Y 89 , less than 0.3 ⁇ 10 ⁇ 27 cm 2 for neutrons of the fission spectrum. It can only occur in reactors with a fast neutron spectrum, and there are few in existence.
- yttrium purified without admixtures of uranium should be used (the uranium content in the Y 2 O 3 pellets must not exceed 10 ⁇ 5 by mass).
- Low productivity and the need for reactors with a fast neutron spectrum are the main problems with this method.
- a solution nuclear reactor containing a uranyl sulfate fuel solution produces krypton-89 during operation.
- Krypton-89 is in the form of a gas that bubbles to the surface of the fuel solution and occupies the enclosed volume above the fuel.
- An inert gas transports the krypton-89, along with other radioisotope fragments, in a sealed system to a trap area where any accompanying relatively short half-life krypton-90 is allowed to decay to strontium-90.
- the strontium-90 is removed.
- the krypton-89 is transported to a catching system where it remains until it fully decays to strontium-89.
- the strontium-89 is removed from the inert gas with the help of sorption in a carbon trap or by chemical interaction in an acid environment.
- the inert gas is returned to the reactor core.
- FIG. 1A shows the fission products decay of Br 89 and Br 90 .
- FIG. 1B shows the fission products decay of Kr 91 .
- FIG. 1C shows fission products decay of Kr 92 and Kr 93 .
- FIG. 2 is a schematic of the gas loop for Sr 89 production.
- the strontium-89 production method is based upon a unique ability to effect not only the final radioisotopes, but also its precursors produced as a result of the nuclear transformation of products in the decay chain of elements with mass 89 occurring in a nuclear solution reactor.
- the decay chain is Se 89 ⁇ Br 89 ⁇ Kr 89 ⁇ Rb 89 ⁇ Sr 89 .
- a liquid fuel nuclear reactor having a uranyl sulfate water solution (UO 2 SO 4 ) core is used in the present invention.
- Uranium-235 and/or uranium-233 can be used as fissionable material in the fuel solution of uranyl sulfate.
- the Russian Argus reactor was the particular reactor used. It used 90% enriched U 235 in a concentration of 73.2 g/l in the water solution.
- the thermal neutron flux density in the central channel is 5 ⁇ 10 11 neutrons/cm 2 s.
- Homogenous solution fuel reactors have a number of advantages over hard fuel reactors. They have large negative temperature and power reactivity effects, which provides for their high nuclear safety.
- the core design is much simpler. There are no fuel element cladding spacers and other parts reducing the neutron characteristics. Solution preparation is much cheaper than fuel element production. Solution fuel loading (pouring) is much easier too, and makes it possible to change the fissionable material concentration in fuel or solution volume if necessary. There can be no local over-heating provoked by power density field deformations in the core of the solution reactor, thanks to good conditions for heat transfer.
- These reactors are simple and reliable in operation and do not require a large staff for their operation.
- a number of radioactive inert gases are produced in uranyl sulfate solution reactor during its operation, including the desired krypton-89. The majority of these gases leave the solution in the gas phase, accumulating above the liquid surface. The process by which this takes place is based on “radiolytic boiling.” Gas bubbles containing water vapor and hydrogen form in the tracks of fission fragments. The vapor is condensed within about 10 ⁇ 8 seconds and a gas bubble forms having a radius of about 10 ⁇ 5 cm. Fission fragments either get into the gaseous bubble during its generation or afterwards by diffusing from the solution. They then migrate to the surface of the fuel solution.
- the radiolytic gas bubbles rise to the surface in only a couple of seconds, making it possible to remove relatively short-life radioisotopes, such as krypton-89. Bubbling the fuel with an inert gas can speed up this process of removal of fragment gases. Krypton-89, along with small quantities of other fission fragment elements are produced at the same time.
- FIGS. 1A to 1 C The main chains of fission products' decay resulting in strontium radionuclides whose gaseous precursors have a half-life of more than one second are shown in FIGS. 1A to 1 C.
- One of the fission products is krypton-89 (Kr 89 ), a radioactive isotope of the inert gas, krypton, preceding strontium-89 in the decay chain of fission products with an atomic mass of 89. It has a half-life of 3.2 minutes, decaying to rubidium-89. Rubidium-89 decays with a half-life of 15.4 minutes to the desired strontium-89.
- the high productivity of this method is primarily the result of: (1) the large cross-section of the decay reaction (n,f) of up to 600-800 ⁇ 10 ⁇ 24 for thermal neutrons for such nuclei as U 235 , U 233 , or Pu 239 ; and (2) the ability to remove the krypton-89 from other gaseous end products of the reaction due to differential decay.
- this method is about 1000 times more efficient than the prior art. Because the half-life of krypton-89 (190.7 seconds) is significantly longer than that of krypton-90 (32.2 seconds), it is possible to decrease the content of strontium-90 in the mixture to about 10 ⁇ 4 atomic percent, providing for high radioisotope purity in the strontium-89.
- FIG. 2 The method of strontium extraction via a continuous gas loop is illustrated in FIG. 2. The process is begun after the transitional processes bound up with the reactor start-up are finished (about 20 minutes). Referring to FIG. 2, valves 3 and 9 are opened and a gas pump 5 is turned on. Gas from above the fuel solution is moved to a delaying line 4 .
- the delaying line is designed to keep the gas from arriving at the precipitation device 7 for the time necessary for krypton-90 to decay to strontium-90, thereby removing it from the gas mixture. Rubidium and strontium isotopes that have not precipitated in the delaying line settle in the filter 6 .
- the diameter of the delaying line pipe is determined by the condition of laminar gas flow in the pipe.
- the pipe's length is determined by the delay time for a preset gas flow rate. (If the gas flow rate is about 2 l/min, a delay time of ten minutes is achieved when the pipe inner diameter is 10 mm and the pipe length is 255 meters. If the diameter were 20 mm, a delay line length of 64 meter would give a 10-minute delay.) A ten minute delay yields a radionuclide purity (Sr 90 /Sr 89 ) of about 3 ⁇ 10 ⁇ 8 .
- the gas arrives at the strontium-89 precipitation device 7 .
- the precipitation device is another pipe whose diameter and length are designed for a delay period sufficient for the remaining krypton-89 to decay to strontium-89. This would be about 11 minutes at a gas flow rate of 2 l/minute.
- the gas less those fission fragments that have precipitated out or otherwise been removed, is return to the reactor.
- the valves 3 , 9 are closed. Strontium-89 deposited in the precipitation device and in the filter 8 are subsequently extracted.
- the circulating gas flow removes water vapor from the fuel solution.
- the initial part of the gas pipe 10 shown in FIG. 2 is inclined so that water vapor is condensed on the pipe wall and the water runs back into the reactor vessel by gravity preventing fuel solution water loss.
- a trap 11 is indicated in FIG. 2 at the entrance to the gas loop to hinder non-gaseous fission fragments moved by the gas flow over the fuel solution from getting into the gas loop.
- the precipitation rate of strontium-89 is high, most of it will accumulate in the precipitation device 7 .
- An acid solution can then be used to wash out strontium-89 from which it is subsequently extracted and subjected to radiochemical purification.
- the precipitation rate is low, most of the strontium-89 will accumulate in the filter 8 .
- This filter can consist of thin, fine nets of stainless steel. The strontium-89 can then be extracted by pumping an acid solution through the filter. Alternatively, a removable filter could be used with extraction of the strontium-89 being done at a later time.
Landscapes
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Plasma & Fusion (AREA)
- General Engineering & Computer Science (AREA)
- High Energy & Nuclear Physics (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
Abstract
Inert gaseous fission products, including beryllium, rubidium, and krypton isotopes, resulting from the operation of a uranyl sulfate water solution nuclear reactor are passed through a delaying device to precipitate out strontium-90, then passed to a second delaying device to precipitate out the desired strontium-89.
Description
- 1. Field of the Invention
- The present invention is in the field of radioisotope production and in particular relates to a method of producing strontium-89.
- 2. Description of the Prior Art
- Radioisotopes have been used in nuclear medicine for diagnostics and therapeutics for more than fifty years. Medical radioisotope production is an important industry using more than 50% of the radioisotopes produced in the world. More than 160 radioisotopes of 80 chemical elements are produced with the help of nuclear reactors and charged particle accelerators today.
- One of the most effective modern therapeutic radioisotopes is strontium-89. It is used for pain palliation instead of drugs when treating cancer. When medicine containing strontium-89 is introduced into an organism, it is absorbed and distributed in the bone metastases providing for a long anesthetic effect.
- Strontium-89 radioisotope has a half-life of 52.7 days with β decay (decays to Y89, a stable isotope). The maximum energy of the β-particles is 1463 keV. The attendant y-radiation energy is 909.1 keV.
- Strontium is a biochemical analog of calcium that has the same transport mechanism in the human body. Strontium chloride SrCl2 introduced to the vein is mainly accumulated in bone metastases providing for a long anesthetic effect so it is not necessary to take drugs frequently and the patient does not become tolerant of them. Malignant tumors tending to metastases in the skeleton are: mammary gland, large intestine, thyroid gland, prostate, kidney, and skin cancer. The maximum range of β-particles of strontium-89 in the bone does not exceed 7 mm, so its radiation effects are isolated to the small area of the skeleton and its radiation burden on the marrow and nearby soft tissue is not significant. As strontium-89 is incorporated in the mineral structure of the bone, diseased metabolism does not take place, and it remains there for more than 100 days. Healthy bone contains a small component of the injected dose and loses it quickly during the first fortnight. One injection of strontium chloride is about 4 mCi and is effective for 3 to 6 months. Clinical tests of the preparation based on 89SrCl3 showed that 65-76% of the patients said that pain had been reduced significantly, and there was full anaesthetic effect in 20% of the cases. In addition, doctors think that strontium-89 chloride has a therapeutic effect, which means it does not only block metastases but also reduces them.
- One reactor method of strontium-89 production consists of irradiating a target of strontium carbonate SrCO3 with neutrons having a thermal neutron spectrum. A target made from metallic strontium is irradiated by the neutron flux of a nuclear reactor. Natural strontium consists of the following isotopes: Sr84 at 0.56%, Sr86 at 9.9%, Sr87 at 7.0% and Sr88 at 82.6%. The strontium-89 radioisotope is formed in the target as a result of the neutron capture reaction of one of the strontium isotopes Sr88(n,y) Sr89. A highly enriched target containing Sr88>99.9% is used because it is necessary to eliminate strontium-85 from the reaction Sr84 (n,y) Sr85, an undesirable admixture. This is a convenient production method and takes place in a normal research reactor. The cross-section of the (n,y)-reaction is only 6×10−27 cm2, however, which restricts the productivity of this method.
- Another strontium-89 production method is based the threshold reaction of neutron capture with the emission of a charged particle Y89 (n,p) Sr89. A target containing natural monoisotope Yttrium-89 is irradiated in the neutron flux of a nuclear reactor with a fast neutron spectrum and is subsequently subjected to radiochemical reprocessing for extraction. Strontium-89 production can achieve about 10-15 mCi per gram of yttrium in optimum conditions. The target is a pellet of yttrium oxide Y2O3 of high purity that is pressed and annealed at 1600° C. This method produces almost no radioactive wastes and the end-product does not contain harmful admixtures, e.g., the quantity of attendant strontium-90 is less than 2×10−4 atomic percent.
- This method has an extremely low productivity due to the small cross-section of the (n,p)-reaction on Y89, less than 0.3×10−27 cm2 for neutrons of the fission spectrum. It can only occur in reactors with a fast neutron spectrum, and there are few in existence. In addition, yttrium purified without admixtures of uranium should be used (the uranium content in the Y2O3 pellets must not exceed 10−5 by mass). Low productivity and the need for reactors with a fast neutron spectrum are the main problems with this method.
- There is clearly a need for a more efficient method for the production of strontium-89, particularly one that uses a relatively low power reactor.
- A solution nuclear reactor containing a uranyl sulfate fuel solution produces krypton-89 during operation. Krypton-89 is in the form of a gas that bubbles to the surface of the fuel solution and occupies the enclosed volume above the fuel. An inert gas transports the krypton-89, along with other radioisotope fragments, in a sealed system to a trap area where any accompanying relatively short half-life krypton-90 is allowed to decay to strontium-90. The strontium-90 is removed. Then the krypton-89 is transported to a catching system where it remains until it fully decays to strontium-89. The strontium-89 is removed from the inert gas with the help of sorption in a carbon trap or by chemical interaction in an acid environment. The inert gas is returned to the reactor core.
- FIG. 1A shows the fission products decay of Br89 and Br90.
- FIG. 1B shows the fission products decay of Kr91.
- FIG. 1C shows fission products decay of Kr92 and Kr93.
- FIG. 2 is a schematic of the gas loop for Sr89 production.
- The strontium-89 production method is based upon a unique ability to effect not only the final radioisotopes, but also its precursors produced as a result of the nuclear transformation of products in the decay chain of elements with
mass 89 occurring in a nuclear solution reactor. The decay chain is Se89→Br89→Kr89→Rb89→Sr89. - A liquid fuel nuclear reactor having a uranyl sulfate water solution (UO2SO4) core is used in the present invention. Uranium-235 and/or uranium-233 can be used as fissionable material in the fuel solution of uranyl sulfate. The Russian Argus reactor was the particular reactor used. It used 90% enriched U235 in a concentration of 73.2 g/l in the water solution. The uranyl sulfate water solution volume (pH=1) was 22 liters. It can be brought up to its rated power of 20 kW in 20 minutes. The thermal neutron flux density in the central channel is 5×1011 neutrons/cm2s.
- Homogenous solution fuel reactors have a number of advantages over hard fuel reactors. They have large negative temperature and power reactivity effects, which provides for their high nuclear safety. The core design is much simpler. There are no fuel element cladding spacers and other parts reducing the neutron characteristics. Solution preparation is much cheaper than fuel element production. Solution fuel loading (pouring) is much easier too, and makes it possible to change the fissionable material concentration in fuel or solution volume if necessary. There can be no local over-heating provoked by power density field deformations in the core of the solution reactor, thanks to good conditions for heat transfer. These reactors are simple and reliable in operation and do not require a large staff for their operation.
- A number of radioactive inert gases are produced in uranyl sulfate solution reactor during its operation, including the desired krypton-89. The majority of these gases leave the solution in the gas phase, accumulating above the liquid surface. The process by which this takes place is based on “radiolytic boiling.” Gas bubbles containing water vapor and hydrogen form in the tracks of fission fragments. The vapor is condensed within about 10−8 seconds and a gas bubble forms having a radius of about 10−5 cm. Fission fragments either get into the gaseous bubble during its generation or afterwards by diffusing from the solution. They then migrate to the surface of the fuel solution. The radiolytic gas bubbles rise to the surface in only a couple of seconds, making it possible to remove relatively short-life radioisotopes, such as krypton-89. Bubbling the fuel with an inert gas can speed up this process of removal of fragment gases. Krypton-89, along with small quantities of other fission fragment elements are produced at the same time.
- The main chains of fission products' decay resulting in strontium radionuclides whose gaseous precursors have a half-life of more than one second are shown in FIGS. 1A to1C. One of the fission products is krypton-89 (Kr89), a radioactive isotope of the inert gas, krypton, preceding strontium-89 in the decay chain of fission products with an atomic mass of 89. It has a half-life of 3.2 minutes, decaying to rubidium-89. Rubidium-89 decays with a half-life of 15.4 minutes to the desired strontium-89. Other isotopes of krypton, however, also bubble to the surface, including the highly undesirable precursor to strontium-90, krypton-90. Krypton-90 decays in 33 seconds to rubidium-90 and in 2.91 minutes to strontium-90. Because krypton-89 and krypton-90 are gases and because of the differential in half-life of the two isotopes, it is relatively easy to separate the two. There is no such possibility in the core of a typical nuclear reactor in which the fissionable material, e.g., U235, is a hard oxide or metal enclosed in the cladding of fuel elements. Other radioactive components with half-lives short compared to krypton-89 can also be readily separated.
- The high productivity of this method is primarily the result of: (1) the large cross-section of the decay reaction (n,f) of up to 600-800×10−24 for thermal neutrons for such nuclei as U235, U233, or Pu239; and (2) the ability to remove the krypton-89 from other gaseous end products of the reaction due to differential decay. For a unit target, this method is about 1000 times more efficient than the prior art. Because the half-life of krypton-89 (190.7 seconds) is significantly longer than that of krypton-90 (32.2 seconds), it is possible to decrease the content of strontium-90 in the mixture to about 10−4 atomic percent, providing for high radioisotope purity in the strontium-89.
- The method of strontium extraction via a continuous gas loop is illustrated in FIG. 2. The process is begun after the transitional processes bound up with the reactor start-up are finished (about 20 minutes). Referring to FIG. 2, valves3 and 9 are opened and a
gas pump 5 is turned on. Gas from above the fuel solution is moved to a delaying line 4. The delaying line is designed to keep the gas from arriving at theprecipitation device 7 for the time necessary for krypton-90 to decay to strontium-90, thereby removing it from the gas mixture. Rubidium and strontium isotopes that have not precipitated in the delaying line settle in the filter 6. The diameter of the delaying line pipe is determined by the condition of laminar gas flow in the pipe. The pipe's length is determined by the delay time for a preset gas flow rate. (If the gas flow rate is about 2 l/min, a delay time of ten minutes is achieved when the pipe inner diameter is 10 mm and the pipe length is 255 meters. If the diameter were 20 mm, a delay line length of 64 meter would give a 10-minute delay.) A ten minute delay yields a radionuclide purity (Sr90/Sr89) of about 3×10−8. - After going through the delaying line, the gas arrives at the strontium-89
precipitation device 7. The precipitation device is another pipe whose diameter and length are designed for a delay period sufficient for the remaining krypton-89 to decay to strontium-89. This would be about 11 minutes at a gas flow rate of 2 l/minute. Those isotopes of rubidium and strontium, which have not precipitated in the precipitation device, pass through it and settle in the filter 8. The gas, less those fission fragments that have precipitated out or otherwise been removed, is return to the reactor. After the cycle of strontium-89 production is completed, the valves 3, 9 are closed. Strontium-89 deposited in the precipitation device and in the filter 8 are subsequently extracted. - The circulating gas flow removes water vapor from the fuel solution. The initial part of the gas pipe10 shown in FIG. 2 is inclined so that water vapor is condensed on the pipe wall and the water runs back into the reactor vessel by gravity preventing fuel solution water loss. A
trap 11 is indicated in FIG. 2 at the entrance to the gas loop to hinder non-gaseous fission fragments moved by the gas flow over the fuel solution from getting into the gas loop. - If the precipitation rate of strontium-89 is high, most of it will accumulate in the
precipitation device 7. An acid solution can then be used to wash out strontium-89 from which it is subsequently extracted and subjected to radiochemical purification. If the precipitation rate is low, most of the strontium-89 will accumulate in the filter 8. This filter can consist of thin, fine nets of stainless steel. The strontium-89 can then be extracted by pumping an acid solution through the filter. Alternatively, a removable filter could be used with extraction of the strontium-89 being done at a later time.
Claims (4)
1. A method of extracting strontium-89 from a uranyl sulfate water solution fueled nuclear reactor, the method comprising:
operating said solution nuclear reactor whereby inert gaseous fission fragments are produced and migrate to the free volume above the solution surface, said gaseous fission fragments comprised of isotopes of beryllium, krypton and rubidium;
pumping said inert gaseous fission fragments through a first delaying device at a flow rate sufficiently slow to allow a desired percent of radioactive krypton-90 to decay to strontium-90, whereby said strontium-90 is precipitated out of the gas;
passing gas through a first filter to remove rubidium and strontium isotopes that were not precipitated in said first delaying device;
pumping remaining gas through a second delaying device (strontium-89 precipitation device) at a flow rate sufficiently slow to allow the decay of the remaining krypton-89 to strontium-89, whereby the desired strontium-89 is precipitated out;
passing gas through a second filter to remove any remaining rubidium and strontium isotopes that were not precipitated out in said strontium-89 precipitation device;
pumping remaining gas back to the reactor; and
extracting precipitated strontium-89 from said strontium-89 precipitation device and from said second filter.
2. The method of claim 1 wherein said first delaying device is comprised of a pipe whose inner diameter and length are calculated for a given gas flow rate to contain the gas for a time sufficient to allow the decay of essentially all the krypton-90 to strontium-90.
3. The method of claim 1 wherein said second delaying device is comprised of a pipe whose inner diameter and length are calculated for a given gas flow rate to contain the gas for a time sufficient to allow the decay of a desired percentage of the krypton-89 to strontium-89.
4. The method of claim 1 wherein the extraction of strontium-89 from said strontium-89 precipitation device and said second filter is by an acid wash.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/538,333 US6456680B1 (en) | 2000-03-29 | 2000-03-29 | Method of strontium-89 radioisotope production |
EP00950418A EP1297536A4 (en) | 2000-03-29 | 2000-07-14 | Method of strontium-89 radioisotope production |
AU2000263526A AU2000263526A1 (en) | 2000-03-29 | 2000-07-14 | Method of strontium-89 radioisotope production |
PCT/US2000/019574 WO2001073792A1 (en) | 2000-03-29 | 2000-07-14 | Method of strontium-89 radioisotope production |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/538,333 US6456680B1 (en) | 2000-03-29 | 2000-03-29 | Method of strontium-89 radioisotope production |
Publications (2)
Publication Number | Publication Date |
---|---|
US20020034275A1 true US20020034275A1 (en) | 2002-03-21 |
US6456680B1 US6456680B1 (en) | 2002-09-24 |
Family
ID=24146483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/538,333 Expired - Fee Related US6456680B1 (en) | 2000-03-29 | 2000-03-29 | Method of strontium-89 radioisotope production |
Country Status (4)
Country | Link |
---|---|
US (1) | US6456680B1 (en) |
EP (1) | EP1297536A4 (en) |
AU (1) | AU2000263526A1 (en) |
WO (1) | WO2001073792A1 (en) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070133734A1 (en) * | 2004-12-03 | 2007-06-14 | Fawcett Russell M | Rod assembly for nuclear reactors |
US20070133731A1 (en) * | 2004-12-03 | 2007-06-14 | Fawcett Russell M | Method of producing isotopes in power nuclear reactors |
US20080027455A1 (en) * | 2004-05-03 | 2008-01-31 | Philippe Boudeville | Composition for Injectable Cement Useful as Bone Replacement |
US20090135987A1 (en) * | 2007-11-28 | 2009-05-28 | Ge-Hitachi Nuclear Energy Americas Llc | Fuel rod designs using internal spacer element and methods of using the same |
US20090135990A1 (en) * | 2007-11-28 | 2009-05-28 | Ge-Hitachi Nuclear Energy Americas Llc | Placement of target rods in BWR bundle |
US20090135983A1 (en) * | 2007-11-28 | 2009-05-28 | Ge-Hitachi Nuclear Energy Americas Llc | Cross-Section Reducing Isotope System |
US20090135988A1 (en) * | 2007-11-28 | 2009-05-28 | Ge-Hitachi Nuclear Energy Americas Llc | Fail-Free Fuel Bundle Assembly |
US20090135989A1 (en) * | 2007-11-28 | 2009-05-28 | Ge-Hitachi Nuclear Energy Americas Llc | Segmented fuel rod bundle designs using fixed spacer plates |
US20090154633A1 (en) * | 2007-12-13 | 2009-06-18 | Fawks Jr James Edward | Tranverse in-core probe monitoring and calibration device for nuclear power plants, and method thereof |
US20090196390A1 (en) * | 2008-02-05 | 2009-08-06 | The Curators Of The University Of Missouri | Radioisotope production and treatment of solution of target material |
US20090213977A1 (en) * | 2008-02-21 | 2009-08-27 | Ge-Hitachi Nuclear Energy Americas Llc | Apparatuses and methods for production of radioisotopes in nuclear reactor instrumentation tubes |
US20090272920A1 (en) * | 2008-05-01 | 2009-11-05 | John Hannah | Systems and methods for storage and processing of radioisotopes |
US20100030008A1 (en) * | 2008-07-30 | 2010-02-04 | Ge-Hitachi Nuclear Energy Americas Llc | Segmented waste rods for handling nuclear waste and methods of using and fabricating the same |
US20100266083A1 (en) * | 2009-04-15 | 2010-10-21 | Ge-Hitachi Nuclear Energy Americas Llc | Method and system for simultaneous irradiation and elution capsule |
US20100266095A1 (en) * | 2009-04-17 | 2010-10-21 | Ge-Hitachi Nuclear Energy Americas Llc | Burnable Poison Materials and Apparatuses for Nuclear Reactors and Methods of Using the Same |
US20110006186A1 (en) * | 2009-07-10 | 2011-01-13 | Ge-Hitachi Nuclear Energy Americas Llc | Brachytherapy and radiography target holding device |
US20110009686A1 (en) * | 2009-07-10 | 2011-01-13 | Ge-Hitachi Nuclear Energy Americas Llc | Method of generating specified activities within a target holding device |
US20110013739A1 (en) * | 2009-07-15 | 2011-01-20 | Ge-Hitachi Nuclear Energy Americas Llc | Methods and apparatuses for producing isotopes in nuclear fuel assembly water rods |
US20110051872A1 (en) * | 2009-08-25 | 2011-03-03 | David Allan Rickard | Irradiation targets for isotope delivery systems |
US20110051874A1 (en) * | 2009-08-25 | 2011-03-03 | Melissa Allen | Irradiation target retention assemblies for isotope delivery systems |
US20110051875A1 (en) * | 2009-08-25 | 2011-03-03 | Bradley Bloomquist | Cable driven isotope delivery system |
US7970095B2 (en) | 2008-04-03 | 2011-06-28 | GE - Hitachi Nuclear Energy Americas LLC | Radioisotope production structures, fuel assemblies having the same, and methods of using the same |
US20110216868A1 (en) * | 2010-03-05 | 2011-09-08 | Russell Ii William Earl | Irradiation target positioning devices and methods of using the same |
EP2259269A4 (en) * | 2008-03-27 | 2011-09-21 | Uchrezhdenie Rossiiskoi Akademii Nauk Inst Yadernykh I Ran Iyai Ran | PROCESS FOR THE PRODUCTION OF RADIOSTRONTIUM |
US8050377B2 (en) | 2008-05-01 | 2011-11-01 | Ge-Hitachi Nuclear Energy Americas Llc | Irradiation target retention systems, fuel assemblies having the same, and methods of using the same |
US8180014B2 (en) | 2007-12-20 | 2012-05-15 | Global Nuclear Fuel-Americas, Llc | Tiered tie plates and fuel bundles using the same |
US8885791B2 (en) | 2007-12-18 | 2014-11-11 | Ge-Hitachi Nuclear Energy Americas Llc | Fuel rods having irradiation target end pieces |
WO2015114424A1 (en) * | 2014-01-31 | 2015-08-06 | Istituto Nazionale Di Fisica Nucleare | Method for producing beta emitting radiopharmaceuticals, and beta emitting radiopharmaceuticals thus obtained |
US9899107B2 (en) | 2010-09-10 | 2018-02-20 | Ge-Hitachi Nuclear Energy Americas Llc | Rod assembly for nuclear reactors |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE460168T1 (en) * | 2003-10-17 | 2010-03-15 | Neurofood Ab Oy | NON-RADIOACTIVE STRONTIUM AGENT FOR THE TREATMENT OF CANCER |
RU2300500C1 (en) * | 2005-11-17 | 2007-06-10 | Федеральное государственное унитарное предприятие "Государственный научный центр Российской Федерации-Научно-исследовательский институт атомных реакторов" | Method of cleaning strontium-89 from yttrium |
RU2307072C2 (en) * | 2005-11-25 | 2007-09-27 | Федеральное государственное унитарное предприятие "Государственный научный центр Российской Федерации - Физико-энергетический институт им. А.И. Лейпунского" | Method of production of the carrier-free strotium-90 with usage of the nuclear water-solution reactor and the device for the method realization |
RU2307071C2 (en) * | 2005-11-25 | 2007-09-27 | Федеральное государственное унитарное предприятие "Государственный научный центр Российской Федерации - Физико-энергетический институт им. А.И. Лейпунского" | Method of production of the carrier-free strotium-90 and the carrier-free strontium-89 with usage of the nuclear water-solution reactor and the device for the method realization |
US8158088B2 (en) * | 2008-11-10 | 2012-04-17 | Battelle Energy Alliance, Llc | Extractant compositions for co-extracting cesium and strontium, a method of separating cesium and strontium from an aqueous feed, and calixarene compounds |
US8270554B2 (en) * | 2009-05-19 | 2012-09-18 | The United States Of America, As Represented By The United States Department Of Energy | Methods of producing cesium-131 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2815321A (en) * | 1945-11-13 | 1957-12-03 | Eugene P Wigner | Isotope conversion device |
US2860093A (en) * | 1945-11-13 | 1958-11-11 | Eugene P Wigner | Isotope conversion device and method |
US3284305A (en) * | 1947-06-02 | 1966-11-08 | Exxon Research Engineering Co | Process of producing energy by nuclear fission |
GB699034A (en) * | 1951-02-20 | 1953-10-28 | Mini Of Supply | Improvements in or relating to the preparation of radioactive isotopes |
US2945794A (en) * | 1952-11-18 | 1960-07-19 | Charles E Winters | Neutronic reactor operational method and core system |
US3080307A (en) * | 1957-10-21 | 1963-03-05 | Westinghouse Electric Corp | Radioactive fluid handling system |
US3154473A (en) * | 1958-03-07 | 1964-10-27 | Hercules Powder Co Ltd | Apparatus for producing controllable slow neutron chain reaction |
DE1189214B (en) * | 1959-12-02 | 1965-03-18 | Asea Ab | Process and reactor system for controlling the amount of fission gas in homogeneous boiler reactors |
US3074776A (en) * | 1960-09-28 | 1963-01-22 | Robert F Ryan | Gaseous disposal process |
DE1444453B2 (en) * | 1962-08-14 | 1970-10-01 | Linde Ag, 6200 Wiesbaden | Method and apparatus for reducing the level of radioactive contaminants in a flowing gas |
US3217471A (en) * | 1962-09-14 | 1965-11-16 | Silverman Leslie | Diffusion board for filtering high pressure gases |
US3635831A (en) * | 1969-09-25 | 1972-01-18 | Atomic Energy Commission | Production of high-purity cesium{14 137 |
DE2060676B2 (en) * | 1970-12-10 | 1974-02-14 | Bergwerksverband Gmbh, 4300 Essen | Process for the removal of radioactive noble gases from the exhaust air of nuclear reactors and reprocessing plants for reactor fuel elements |
SE349887B (en) * | 1971-02-10 | 1972-10-09 | Asea Atom Ab | |
AT340011B (en) * | 1972-04-01 | 1977-11-25 | Bergwerksverband Gmbh | PROCESS FOR EXHAUST GAS TREATMENT OF RADIOACTIVE ACTIVATING GASES |
US3944646A (en) * | 1972-05-11 | 1976-03-16 | Union Carbide Corporation | Radioactive krypton gas separation |
US4012490A (en) * | 1972-07-25 | 1977-03-15 | Airco, Inc. | Removing radioactive noble gases from nuclear process off-gases |
US4532102A (en) * | 1983-06-01 | 1985-07-30 | The United States Of America As Represented By The United States Department Of Energy | Producing tritium in a homogenous reactor |
US5596611A (en) * | 1992-12-08 | 1997-01-21 | The Babcock & Wilcox Company | Medical isotope production reactor |
RU2102808C1 (en) * | 1996-06-04 | 1998-01-20 | Государственный научный центр РФ "Институт ядерных исследований РАН" | Radiostrontium production process |
-
2000
- 2000-03-29 US US09/538,333 patent/US6456680B1/en not_active Expired - Fee Related
- 2000-07-14 AU AU2000263526A patent/AU2000263526A1/en not_active Abandoned
- 2000-07-14 EP EP00950418A patent/EP1297536A4/en not_active Withdrawn
- 2000-07-14 WO PCT/US2000/019574 patent/WO2001073792A1/en not_active Application Discontinuation
Cited By (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080027455A1 (en) * | 2004-05-03 | 2008-01-31 | Philippe Boudeville | Composition for Injectable Cement Useful as Bone Replacement |
US8440737B2 (en) * | 2004-05-03 | 2013-05-14 | Centre National De La Recherche Scientifique | Composition for injectable cement useful as bone replacement |
US9239385B2 (en) | 2004-12-03 | 2016-01-19 | General Electric Company | Method of producing isotopes in power nuclear reactors |
US20070133731A1 (en) * | 2004-12-03 | 2007-06-14 | Fawcett Russell M | Method of producing isotopes in power nuclear reactors |
US7526058B2 (en) | 2004-12-03 | 2009-04-28 | General Electric Company | Rod assembly for nuclear reactors |
US20090122946A1 (en) * | 2004-12-03 | 2009-05-14 | Russell Morgan Fawcett | Rod assembly for nuclear reactors |
US20070133734A1 (en) * | 2004-12-03 | 2007-06-14 | Fawcett Russell M | Rod assembly for nuclear reactors |
US8842801B2 (en) | 2004-12-03 | 2014-09-23 | General Electric Company | Rod assembly for nuclear reactors |
US8953731B2 (en) | 2004-12-03 | 2015-02-10 | General Electric Company | Method of producing isotopes in power nuclear reactors |
US20090135987A1 (en) * | 2007-11-28 | 2009-05-28 | Ge-Hitachi Nuclear Energy Americas Llc | Fuel rod designs using internal spacer element and methods of using the same |
US9362009B2 (en) | 2007-11-28 | 2016-06-07 | Ge-Hitachi Nuclear Energy Americas Llc | Cross-section reducing isotope system |
US20090135989A1 (en) * | 2007-11-28 | 2009-05-28 | Ge-Hitachi Nuclear Energy Americas Llc | Segmented fuel rod bundle designs using fixed spacer plates |
US9202598B2 (en) | 2007-11-28 | 2015-12-01 | Ge-Hitachi Nuclear Energy Americas Llc | Fail-free fuel bundle assembly |
US20090135988A1 (en) * | 2007-11-28 | 2009-05-28 | Ge-Hitachi Nuclear Energy Americas Llc | Fail-Free Fuel Bundle Assembly |
US8842800B2 (en) | 2007-11-28 | 2014-09-23 | Ge-Hitachi Nuclear Energy Americas Llc | Fuel rod designs using internal spacer element and methods of using the same |
US20090135983A1 (en) * | 2007-11-28 | 2009-05-28 | Ge-Hitachi Nuclear Energy Americas Llc | Cross-Section Reducing Isotope System |
US20090135990A1 (en) * | 2007-11-28 | 2009-05-28 | Ge-Hitachi Nuclear Energy Americas Llc | Placement of target rods in BWR bundle |
US20090154633A1 (en) * | 2007-12-13 | 2009-06-18 | Fawks Jr James Edward | Tranverse in-core probe monitoring and calibration device for nuclear power plants, and method thereof |
US9025719B2 (en) | 2007-12-13 | 2015-05-05 | Ge-Hitachi Nuclear Energy Americas Llc | Transverse in-core probe monitoring and calibration device for nuclear power plants, and method thereof |
US8712000B2 (en) * | 2007-12-13 | 2014-04-29 | Global Nuclear Fuel—Americas, LLC | Tranverse in-core probe monitoring and calibration device for nuclear power plants, and method thereof |
US8885791B2 (en) | 2007-12-18 | 2014-11-11 | Ge-Hitachi Nuclear Energy Americas Llc | Fuel rods having irradiation target end pieces |
US20120189090A1 (en) * | 2007-12-20 | 2012-07-26 | Defilippis Michael S | Tiered Tie Plates and Fuel Bundles Using the Same |
US8180014B2 (en) | 2007-12-20 | 2012-05-15 | Global Nuclear Fuel-Americas, Llc | Tiered tie plates and fuel bundles using the same |
US8599995B2 (en) * | 2007-12-20 | 2013-12-03 | Global Nuclear Fuel-Americas, Llc | Tiered tie plates and fuel bundles using the same |
US20090196390A1 (en) * | 2008-02-05 | 2009-08-06 | The Curators Of The University Of Missouri | Radioisotope production and treatment of solution of target material |
US8644442B2 (en) * | 2008-02-05 | 2014-02-04 | The Curators Of The University Of Missouri | Radioisotope production and treatment of solution of target material |
US8437443B2 (en) | 2008-02-21 | 2013-05-07 | Ge-Hitachi Nuclear Energy Americas Llc | Apparatuses and methods for production of radioisotopes in nuclear reactor instrumentation tubes |
US20090213977A1 (en) * | 2008-02-21 | 2009-08-27 | Ge-Hitachi Nuclear Energy Americas Llc | Apparatuses and methods for production of radioisotopes in nuclear reactor instrumentation tubes |
US8842798B2 (en) | 2008-02-21 | 2014-09-23 | Ge-Hitachi Nuclear Energy Americas Llc | Apparatuses and methods for production of radioisotopes in nuclear reactor instrumentation tubes |
EP2259269A4 (en) * | 2008-03-27 | 2011-09-21 | Uchrezhdenie Rossiiskoi Akademii Nauk Inst Yadernykh I Ran Iyai Ran | PROCESS FOR THE PRODUCTION OF RADIOSTRONTIUM |
US7970095B2 (en) | 2008-04-03 | 2011-06-28 | GE - Hitachi Nuclear Energy Americas LLC | Radioisotope production structures, fuel assemblies having the same, and methods of using the same |
US20110206175A1 (en) * | 2008-04-03 | 2011-08-25 | David Grey Smith | Radioisotope production structures, fuel assemblies having the same, and methods of using the same |
US8576972B2 (en) | 2008-04-03 | 2013-11-05 | Ge-Hitachi Nuclear Energy Americas Llc | Radioisotope production structures, fuel assemblies having the same, and methods of using the same |
US8270555B2 (en) | 2008-05-01 | 2012-09-18 | Ge-Hitachi Nuclear Energy Americas Llc | Systems and methods for storage and processing of radioisotopes |
US8050377B2 (en) | 2008-05-01 | 2011-11-01 | Ge-Hitachi Nuclear Energy Americas Llc | Irradiation target retention systems, fuel assemblies having the same, and methods of using the same |
US20090272920A1 (en) * | 2008-05-01 | 2009-11-05 | John Hannah | Systems and methods for storage and processing of radioisotopes |
US20100030008A1 (en) * | 2008-07-30 | 2010-02-04 | Ge-Hitachi Nuclear Energy Americas Llc | Segmented waste rods for handling nuclear waste and methods of using and fabricating the same |
US7781637B2 (en) | 2008-07-30 | 2010-08-24 | Ge-Hitachi Nuclear Energy Americas Llc | Segmented waste rods for handling nuclear waste and methods of using and fabricating the same |
US20100266083A1 (en) * | 2009-04-15 | 2010-10-21 | Ge-Hitachi Nuclear Energy Americas Llc | Method and system for simultaneous irradiation and elution capsule |
US8699651B2 (en) * | 2009-04-15 | 2014-04-15 | Ge-Hitachi Nuclear Energy Americas Llc | Method and system for simultaneous irradiation and elution capsule |
US9396825B2 (en) | 2009-04-15 | 2016-07-19 | Ge-Hitachi Nuclear Energy Americas Llc | Method and system for simultaneous irradiation and elution capsule |
US9165691B2 (en) | 2009-04-17 | 2015-10-20 | Ge-Hitachi Nuclear Energy Americas Llc | Burnable poison materials and apparatuses for nuclear reactors and methods of using the same |
US20100266095A1 (en) * | 2009-04-17 | 2010-10-21 | Ge-Hitachi Nuclear Energy Americas Llc | Burnable Poison Materials and Apparatuses for Nuclear Reactors and Methods of Using the Same |
US9431138B2 (en) | 2009-07-10 | 2016-08-30 | Ge-Hitachi Nuclear Energy Americas, Llc | Method of generating specified activities within a target holding device |
US20110009686A1 (en) * | 2009-07-10 | 2011-01-13 | Ge-Hitachi Nuclear Energy Americas Llc | Method of generating specified activities within a target holding device |
US20110006186A1 (en) * | 2009-07-10 | 2011-01-13 | Ge-Hitachi Nuclear Energy Americas Llc | Brachytherapy and radiography target holding device |
US8366088B2 (en) | 2009-07-10 | 2013-02-05 | Ge-Hitachi Nuclear Energy Americas Llc | Brachytherapy and radiography target holding device |
US20110013739A1 (en) * | 2009-07-15 | 2011-01-20 | Ge-Hitachi Nuclear Energy Americas Llc | Methods and apparatuses for producing isotopes in nuclear fuel assembly water rods |
US8638899B2 (en) | 2009-07-15 | 2014-01-28 | Ge-Hitachi Nuclear Energy Americas Llc | Methods and apparatuses for producing isotopes in nuclear fuel assembly water rods |
US20110051875A1 (en) * | 2009-08-25 | 2011-03-03 | Bradley Bloomquist | Cable driven isotope delivery system |
US9183959B2 (en) | 2009-08-25 | 2015-11-10 | Ge-Hitachi Nuclear Energy Americas Llc | Cable driven isotope delivery system |
US8488733B2 (en) | 2009-08-25 | 2013-07-16 | Ge-Hitachi Nuclear Energy Americas Llc | Irradiation target retention assemblies for isotope delivery systems |
US20110051874A1 (en) * | 2009-08-25 | 2011-03-03 | Melissa Allen | Irradiation target retention assemblies for isotope delivery systems |
US20110051872A1 (en) * | 2009-08-25 | 2011-03-03 | David Allan Rickard | Irradiation targets for isotope delivery systems |
US9589691B2 (en) | 2009-08-25 | 2017-03-07 | Ge-Hitachi Nuclear Energy Americas Llc | Method of producing isotopes in a nuclear reactor with an irradiation target retention system |
US9773577B2 (en) | 2009-08-25 | 2017-09-26 | Ge-Hitachi Nuclear Energy Americas Llc | Irradiation targets for isotope delivery systems |
US20110216868A1 (en) * | 2010-03-05 | 2011-09-08 | Russell Ii William Earl | Irradiation target positioning devices and methods of using the same |
US8542789B2 (en) | 2010-03-05 | 2013-09-24 | Ge-Hitachi Nuclear Energy Americas Llc | Irradiation target positioning devices and methods of using the same |
US9899107B2 (en) | 2010-09-10 | 2018-02-20 | Ge-Hitachi Nuclear Energy Americas Llc | Rod assembly for nuclear reactors |
WO2015114424A1 (en) * | 2014-01-31 | 2015-08-06 | Istituto Nazionale Di Fisica Nucleare | Method for producing beta emitting radiopharmaceuticals, and beta emitting radiopharmaceuticals thus obtained |
EP3100279B1 (en) * | 2014-01-31 | 2018-10-10 | Istituto Nazionale di Fisica Nucleare | Method for producing beta emitting radiopharmaceuticals |
Also Published As
Publication number | Publication date |
---|---|
EP1297536A4 (en) | 2003-09-03 |
US6456680B1 (en) | 2002-09-24 |
WO2001073792A1 (en) | 2001-10-04 |
EP1297536A1 (en) | 2003-04-02 |
AU2000263526A1 (en) | 2001-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6456680B1 (en) | Method of strontium-89 radioisotope production | |
EP1058931B1 (en) | Method and apparatus for the production and extraction of molybdenum-99 | |
AU635619B2 (en) | Process for producing actinium-225 and bismuth-213 | |
EP0990238B1 (en) | Neutron-driven element transmutation | |
AU2009212487B2 (en) | Radioisotope production and treatment of solution of target material | |
Lee et al. | Development of fission 99Mo production process using HANARO | |
Artiani et al. | Radioactive fission waste from molybdenum-99 production and proliferation risks | |
Ruth | The production of 18F F2 and 15O O2 sequentially from the same target chamber | |
CN112863726B (en) | A method and system for producing high activity ratio Sr-89 and Sr-90 in a liquid molten salt reactor | |
Chuvilin et al. | An interleaved approach to production of 99 Mo and 89 Sr medical radioisotopes | |
RU2430440C1 (en) | Bismuth-212 radionuclide obtaining method | |
Chuvilin et al. | Production of 89Sr in solution reactor | |
Shikata et al. | Production of 99 Mo and its application in nuclear medicine | |
RU2276816C2 (en) | Method for producing strontium-89 radioisotope | |
RU2276817C2 (en) | Method for producing strontium-89 radioisotope | |
Setiadipura et al. | Neutronic aspect of Subcritical Assemby for Mo-99 Production (SAMOP) Reactor | |
Malikov et al. | Prospects for the application of nuclear reactor with homogeneous solution fuel for the production of medical radioisotopes | |
Hayes | Applications of Fission | |
Vega | Design of a Subcritical Aqueous Target System for Medical Isotope Production | |
Oh et al. | Development of key technology for the medical isotope production | |
Sutherland | Producing Medical Radioisotopes with CANDU Nuclear Reactors | |
Shaheen et al. | Anomalous deuteron to hydrogen ratio in Oklo samples and the possibility of deuteron disintegration | |
Vuksanovic et al. | Development of radioisotope production on the accelerator installation Tesla | |
Kosyakov | Perspective methods for Berkelium–249 preparation and application | |
Inaba | Development of 99 Mo Production Technology with Solution Irradiation Method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TCI INCORPORATED, NEW MEXICO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ABALIN, S.S.;VERESCHAGIN, Y.I.;GROGORIEV, G.Y.;AND OTHERS;REEL/FRAME:010966/0836;SIGNING DATES FROM 20000425 TO 20000428 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20100924 |